Transparency Market Research
(TMR) has published a new report titled, “Gynecology Drugs Market - Global
Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.
According to the report, the global gynecology drugs market was valued
at US$ 53.376.96 Mn in 2017. It is projected to expand at a CAGR of 5.5% during
forecast period. The global gynecology drugs market is anticipated to be driven
by rising incidence and prevalence rate of gynecological diseases during the
forecast period. The gynecology drugs market in Asia Pacific is expected to
expand at a high CAGR of 6.3%, due to the high prevalence of diseases, improvements
in the health care sector, and increasing focus of key players on business
expansion.
Worldwide increase in the
prevalence of gynecological disorders
Gynecologic disorders affect the
female reproductive system. The most common symptoms of gynecologic disorders
include pelvic pain, vaginal itching, vaginal discharge, abnormal vaginal
bleeding, and breast pain and lumps. The significance and severity of these
symptoms often depend on age, as these symptoms may be related to hormonal
changes that occur with aging.
Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=54756
Among other prominent
gynecological diseases, sexually transmitted disease (STD) is the most common
and critical – the most common STD among women is pelvic inflammatory disease.
In the U.S. alone, more than one million women suffer from this disorder in
their lifetime, followed by chlamydia – a sexually transmitted infection of the
vagina, which, if left untreated, develops into pelvic inflammatory disease.
Gynecological disorders may or may not be related to the menstrual cycle, which
prominently include menstrual cramps and endometriosis (abnormally located
patches of tissue that is normally located only in the lining of the uterus).
Additionally, gynecological cancers are also common among women around the
globe. Endometrial cancer and ovarian cancer are highly common among women.
Therefore, increase in the prevalence of the conditions mentioned above, are
likely to increase the uptake of gynecology drugs.
Rise in number of women facing
menopausal conditions
Rise in number of women facing
menopausal condition is a major factor that is expected to drive the market
during the forecast period. Menopause is defined as permanent cessation of
menstruation, resulting from loss of activity of ovarian follicles. In a
majority of women, menopause is a natural event occurring at the age of around
51.3 years. The number of women entering menopausal condition is increasing
year on year, due to unhealthy lifestyle and different environmental factors.
In Canada, presently, over five
million women aged between 45 and 65 have either gone through menopause or are
expected to soon go through menopause. The average age of menopause in Canada
is 51 years. Moreover, according to the Society of Obstetricians &
Gynecologists of Canada, around 80% women claim to suffer from at least one
menopausal symptom including mood swings, irritability, interrupted sleep, hot
flashes, and vaginal dryness. Incidence of menopausal vasomotor symptoms has
risen significantly in the last few years, which in turn drives the global
gynecology drugs market.
Request for Analysis of COVID19 Impact on Gynecology
Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=54756
The global gynecology drugs
market has been segmented based on therapeutics, indication, distribution
channel, and region. Furthermore, in terms of therapeutics, the market has been
divided into hormonal therapy and non-hormonal therapy. The non-hormonal
therapy segment is likely to account for a leading share of the global market
during the forecast period owing to the effectiveness of the products, rising
adoption of these products, and new product development.
Decreasing use of hormonal
products due to the risk of breast cancer has boosted the demand for
non-hormonal pharmaceutical products. In terms of indication, the market has
been classified into gynecology cancers, endometriosis, female infertility,
menopausal disorder, gynecology infections, polycystic ovary syndrome,
contraception (birth control), and others. In terms of distribution channel,
the market has been segregated into hospital pharmacies, retail pharmacies, and
online pharmacies. The online pharmacies segment is projected to expand at a
significant CAGR during the forecast period, owing to the ease of using online
pharmacy and rise in the number of internet users.
Purchase Gynecology Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=54756<ype=S
Huge patient base of
gynecology disease in Asia Pacific to create opportunities in market
In terms of region, the global
gynecology devices market has been segmented into five major regions: North
America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is projected to hold a leading share of the global market during
the forecast period, owing to high rate of adoption of technological advanced
products, presence of key players, and high health care expenditure. Europe is
anticipated to account for a significant share of the global market between
2018 and 2026. Increase in incidence of gynecological diseases is expected to
fuel the market in the region during the forecast period. The market in Asia
Pacific is likely to witness robust expansion during the forecast period, due
to surge in health care expenditure. Moreover, increasing focus of key players
on expansion in Asia Pacific, large untapped population in the region, and
rising awareness about health care drive the gynecology drugs market in Asia
Pacific. The gynecology drugs market in Latin America and Middle East &
Africa is anticipated to expand at a steady pace from 2018 to 2026.
Key players profiled in this
report are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., Sanofi,
Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche
Ltd., Allergan Plc, GlaxoSmithKline plc, Bayer AG, and Johnson & Johnson.
Companies operating in the global gynecology drugs market focus on strategic
collaborations to develop new products in emerging markets such as Asia Pacific
and Latin America.
More Trending Reports by Transparency Market Research –
Bone Grafts and Substitutes Market: https://www.biospace.com/article/bone-grafts-and-substitutes-market-ceramic-based-bone-grafts-and-substitutes-to-be-a-highly-lucrative-segment/
Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
About Us
Transparency Market Research is a
global market intelligence company providing global business information reports
and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for several decision makers. Our
experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
Our data repository is
continuously updated and revised by a team of research experts so that it
always reflects latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com/
